A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (NCT04669171)
A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Who can join: Review the eligibility criteria below.
Location: Dana Farber Cancer Institute — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Dana Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) — Rochester, New York
- University of Washington-Seattle Cancer Care Alliance — Seattle, Washington
- CHU d'Amiens-Picardie - Hopital SUD — Amiens,
- University of Bologna — Bologna,
- IRCCS Policlinico San Matteo Foundation - University of Pavia — Naples,
- IRCCS Policlinico San Matteo Foundation - University of Pavia — Pavia,
- University Hospital Vall d'Hebron, Institute of Oncology — Barcelona,
- Clinica Universidad de Navarra — Madrid,
- Clinica Universidad de Navarra — Pamplona,
- Hospital Clinico Universitario de Salamanca — Salamanca,
📞 Contact the Study Coordinator
Phone: (323) 205-5555
Email: medicalmonitoring-hem@enterome.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Follicular Lymphoma
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas — New York, New York
- Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma — Bethesda, Maryland
- Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma — Basking Ridge, New Jersey
- Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma — New York, New York
- Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma — Boston, Massachusetts
- A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Concord, California
Explore by condition: All Follicular Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.